Prices of 18 new drug formulations are capped in IndiaBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6006 (Published 09 November 2015) Cite this as: BMJ 2015;351:h6006
The National Pharmaceutical Pricing Authority of India has capped the prices of 18 new drug formulations, including an intrauterine contraceptive device, antibiotics, painkillers, and drugs for diabetes and hypertension.
The prices have been capped under the Drugs Price Control Order (DPCO) 2013, which establishes a market based pricing mechanism to control the costs of drugs in India.
Sharmila Mary Joseph, member secretary at the National Pharmaceutical Pricing Authority, told The BMJ that these 18 formulations were related to the price controlled schedule I drugs of the DPCO, which include the 2011 National List of Essential Medicines of India. They may be a modification or a combination of drugs on the schedule I list or a combination of a schedule I drug with a new drug, she said. Under DPCO 2013 the manufacturers of new formulations containing schedule I drugs must apply for price approval before launch. So far the ceiling prices of 530 schedule I drugs and the retail prices of 247 new formulations containing schedule I drugs have been fixed, she added.
The latest formulations to have their prices capped include metformin hydrochloride 1000 mg (prolonged release; Rs3.40 (£0.03; €0.05; $0.05) per tablet); aceclofenac 100 mg plus paracetamol 325 mg tablets (Mahadol; Rs2.77 per tablet); metformin hydrochloride 500 mg (sustained release) plus voglibose 0.2 mg plus glimepiride 1 mg (Rs71.43 for 10 tablets); metformin hydrochloride 500 mg (sustained release) plus voglibose 0.2 mg plus glimepiride 2 mg (Rs90.48 for 10 tablets); levonorgestrel releasing intrauterine device (Rs4652.45 per device); cefixime dry syrup (Rs1.39 per mL); ofloxacin 200 mg plus ornidazole 500 mg (Brutaflox–OZ; Rs6.60 per tablet); bisoprolol fumarate plus amlodipine (CORBIS AM 2.5/5; Rs61.78 for 10 tablets; CORBIS AM 5/5; Rs73.36 for 10 tablets).
The products are made by companies including Cipla, Merck, Inventia Healthcare, Zuventus Healthcare, Alembic Pharmaceuticals, and Apex Lab.
Cite this as: BMJ 2015;351:h6006